Is AI making enzyme engineering as simple as coding? China's first "Omics+" Enzyme Agent upgrades!

Recently, the AI-driven biomanufacturing enterpriseXinbeilai BiotechnologyAnnounces major upgrade to its Xuanzhu Computing Core Platform, SynGears.Successfully built China's first "Omics+" enzyme AI agent, SynGears Omni.。

This is not only a technical iteration for Xinbeilai, but also fills a critical gap in the current...AI-Driven BiomanufacturingFills the upstream gap in multi-omics source mining, delivering the industry's first end-to-end automated closed loop from raw sequencing data to industrial biomanufacturing. This drives a shift from fragmented optimization to foundational innovation at the source.

[Pain Point: The Fragmented Dilemma of Biomanufacturing]

For years, mainstream global AI bio-computation tools have been constrained by two persistent industry barriers that significantly extend R&D cycles and raise the bar for innovation:

First, fragmented workflows and a lack of capability to identify root causes.Most AI platforms on the market focus solely on known protein engineering and optimized metabolic pathways in established strains, lacking the capability to independently perform deep analysis of raw sequencing data from genomics, transcriptomics, and metabolomics. After receiving sequencing files, researchers must manually switch between over a dozen bioinformatics tools and access overseas public databases to clean, align, and annotate data. This entire process often takes weeks or even months, and the data cannot automatically flow into downstream enzyme mining and pathway design stages.R&D progress is fragmented and disjointed throughout the entire process.。

Second, the safety of core biological assets is not guaranteed.Strain-specific sequences, natural product biosynthesis genes, and custom enzyme sequences constitute core industrial secrets for enterprises. Traditional cloud-based sharing models pose data leakage risks, while overseas tools fail to meet domestic companies' needs for localized, sovereign-controlled data storage and computation, creating significant intellectual property protection concerns.

Under dual bottlenecks, industry innovation remains stuck at "midstream improvements," unable to tap into the species' genetic blueprint for entirely new functional enzymes and synthetic pathways. This has long constrained the R&D efficiency of biosynthesis for natural products and high-value-added intermediates.

Breaking the Mold: SynGears Omni's "Source-Level Innovation"

The latest SynGears Omni upgrade builds on Xuanzhu Computing's existing protein AI design foundation, adding an integrated multi-omics mining module and featuring a self-scheduling AI agent architecture to deliver a complete source-innovation workflow.

All-in-one automated multi-omics analysis

The platform automatically ingests diverse raw sequencing data to perform integrated, deep multi-omics mining and gene function analysis in a single workflow—eliminating the need for manual file conversion or cross-software processing. AI agents automatically process omics analysis results and directly integrate with three core downstream R&D modules:New Features: Enzyme Discovery, Rational Protein Design, and Intelligent Screening of Biosynthetic Pathways for Target Products, implement "One dataset, end-to-end reuse”。

Underlying architecture ensures localized, autonomous control of highly sensitive data

To meet industrial-grade biotech R&D data security requirements, SynGears Omni designs a localized deployment solution at the foundational compute architecture level. Enterprise core sequencing data, proprietary gene sequences, and custom enzyme models are retained and processed entirely on local servers—eliminating reliance on overseas databases or public cloud transmission. This ensures end-to-end data sovereignty and autonomy, mitigating the risk of core bio-asset leakage from the source. It aligns with intellectual property protection needs for enterprises in pharmaceuticals, fine chemicals, and bio-based materials.

Achieve end-to-end full automation from sequencing to industrial conversion

SynGears Omni isThe first commercial computational platform to integrate multi-omics source mining into a unified AI agent system.Decode the genetic information of unknown species from scratch, discover entirely new functional elements in nature, and use AI to engineer proteins and construct pathways. This delivers a complete solution ready for fermentation and pilot-scale deployment—truly advancing biomanufacturing innovation from "fragmental improvement" to "source-level native innovation."

The global competition in the biomanufacturing industry has evolved from focusing solely on fermentation processes and strain engineering to competing for upstream capabilities in digitally mining genetic resources.Multi-omicsis a core tool for interpreting biological genetic resources.AI AgentIt is the scheduling core that connects the entire R&D workflow. Together, they will become essential infrastructure for future enterprises and research institutions.

As biomanufacturing shifts from "fragmented innovation" to "foundational innovation," and AI Agents bridge the entire journey from raw sequencing data to industrial scale-up, the efficiency of creation will be redefined.

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)will be8 27-28Held in Shanghai, the exhibition will invite2000+ Attendees,100+Speaker,20+Premium exhibitors, featuring "Exhibitions - Conferences - Meetings - EventsFour core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."

Exhibition FocusMedical Aesthetics, Bio-based Materials & Green Chemicals, Food, Agriculture, and AI EmpowermentExhibitor recruitment is now open. Contact us for details on participating in the exhibition.